After more than 40 years of standard first-line anthracycline therapy olaratumab, a platelet-derived growth factor receptor alpha (PDGFRα) inhibitor, in combination with doxorubicin raised hope for a new first-line therapeutic option for advanced STS patients [4]; however, results of the phase III study could not confirm the initially observed OS benefit. Here, PDGFRA is linked to telomere syndrome.